Education
About Us
Working with TipRanks
Follow Us
Julie Smith Insider Profile
4 Followers
Julie Smith, President & CEO, Director at Raptor Pharmaceutical Corp., holds 10.78K shares in Exelixis (Ticker: EXEL), holds 37.95K shares in Raptor Pharmaceutical Corp. (Ticker: RPTP), holds ― shares in Audentes Therapeutics (Ticker: ~BOLD).
Julie Smith Raptor Pharmaceutical Corp. (RPTP)President & CEO, Director
Raptor Pharmaceutical Corp. (RPTP)
President & CEO, Director
Ranked #86,087 out of 100,956 Corporate Insiders
Profitable Transactions
1 out of 3 Profitable Transactions
Average Return
-40.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Julie Smith
Julie Smith's Trading History
Raptor Pharmaceutical Corp.
Feb 11, 2016
―
Uninformative Buy
―
$341.55K
Exelixis
Feb 28, 2025
Director
Uninformative Buy
1.48M
$415.82K
Audentes Therapeutics
―
―
―
―
Stoke Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Julie Smith's performance on stock
You May Also Like
Julie Smith insider profile FAQ
What is the percentage of profitable transactions made by Julie Smith?
The percentage of profitable transactions made by Julie Smith is 33%.
What is the average return per transaction made by Julie Smith?
The average return per transaction made by Julie Smith is -40.60%.
What stocks does Julie Smith hold?
Julie Smith holds: RPTP, EXEL, ~BOLD, STOK stocks.
What was Julie Smith’s latest transaction?
Julie Smith latest transaction was an Uninformative Buy of $1.48M.
What was Julie Smith's most profitable transaction?
Julie Smith’s most profitable transaction was an Informative Sell of EXEL stock on February 28, 2025. The return on the trade was 0.20%.
What is Julie Smith's role in Raptor Pharmaceutical Corp.?
Julie Smith's role in Raptor Pharmaceutical Corp. is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.